Drug Profile
Research programme: antibacterials - Invenux
Alternative Names: Antibacterials research programme - Invenux; Monobactams research programme - InvenuxLatest Information Update: 18 Apr 2005
Price :
$50
*
At a glance
- Originator Invenux (CEASED)
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 31 Dec 2004 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 13 Jan 2002 Preclinical development for Bacterial infections in USA (Unknown route)